Helga Salvesen

Helga Salvesen's AcademicInfluence.com Rankings

Helga Salvesen

Philosophy

#10803

World Rank

#14826

Historical Rank

Logic

#7651

World Rank

#9479

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Why Is Helga Salvesen Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Helga Birgitte Salvesen was a Norwegian physician and professor of medicine at the University of Bergen. Early life and education Salvesen was born in Asker, but moved to Bergen at the age of four. She took the cand.med. degree in 1991 and the dr.med. degree in 2000, with the doctoral thesis Tumor Biomarkers and Prognostic Factors in Endometrial Carcinoma.

(See a Problem?)

Helga Salvesen's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Integrated genomic characterization of endometrial carcinoma (2013) (3708)
Comprehensive genomic profiles of small cell lung cancer (2015) (1397)
Gene expression in fixed tissues and outcome in hepatocellular carcinoma. (2008) (1158)
Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk (2015) (838)
EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. (2006) (784)
Integrated genomic and molecular characterization of cervical cancer (2017) (762)
Landscape of genomic alterations in cervical carcinomas (2013) (676)
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer (2013) (534)
Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. (2011) (474)
GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer (2013) (350)
Drug-sensitive FGFR2 mutations in endometrial carcinoma (2008) (346)
PTEN methylation is associated with advanced stage and microsatellite instability in endometrial carcinoma (2001) (290)
Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation (2009) (274)
Integrated Genome-Wide DNA Copy Number and Expression Analysis Identifies Distinct Mechanisms of Primary Chemoresistance in Ovarian Carcinomas (2009) (265)
Markers for individualised therapy in endometrial carcinoma. (2012) (230)
Prognostic significance of angiogenesis and Ki-67, p53, and p21 expression: a population-based endometrial carcinoma study. (1999) (197)
Significance of tumour‐associated macrophages, vascular endothelial growth factor and thrombospondin‐1 expression for tumour angiogenesis and prognosis in endometrial carcinomas (1999) (177)
Identification of six new susceptibility loci for invasive epithelial ovarian cancer (2014) (176)
PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS (2016) (174)
The genomic landscape and evolution of endometrial carcinoma progression and abdominopelvic metastasis (2016) (168)
Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer (2013) (167)
Profiles of Genomic Instability in High-Grade Serous Ovarian Cancer Predict Treatment Outcome (2012) (158)
Correlation of Smoking-Associated DNA Methylation Changes in Buccal Cells With DNA Methylation Changes in Epithelial Cancer. (2015) (158)
Prognostic impact of alterations in P-cadherin expression and related cell adhesion markers in endometrial cancer. (2004) (157)
Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. (2016) (146)
Genome-wide association study identifies a common variant associated with risk of endometrial cancer (2011) (142)
Frequency and prognostic impact of microsatellite instability in a large population-based study of endometrial carcinomas. (2000) (140)
Loss of nuclear p16 protein expression is not associated with promoter methylation but defines a subgroup of aggressive endometrial carcinomas with poor prognosis. (2000) (137)
Hormone receptor loss in endometrial carcinoma curettage predicts lymph node metastasis and poor outcome in prospective multicentre trial. (2013) (134)
Methylation of hMLH1 in a population-based series of endometrial carcinomas. (2000) (132)
Role of DNA Methylation and Epigenetic Silencing of HAND2 in Endometrial Cancer Development (2013) (131)
HOTAIR and its surrogate DNA methylation signature indicate carboplatin resistance in ovarian cancer (2015) (131)
Lack of Estrogen Receptor-α Is Associated with Epithelial–Mesenchymal Transition and PI3K Alterations in Endometrial Carcinoma (2013) (130)
Stathmin Overexpression Identifies High-Risk Patients and Lymph Node Metastasis in Endometrial Cancer (2011) (119)
The Dynamics and Prognostic Potential of DNA Methylation Changes at Stem Cell Gene Loci in Women's Cancer (2012) (115)
Vascular proliferation is important for clinical progress of endometrial cancer. (2006) (115)
A novel wnt regulatory axis in endometrioid endometrial cancer. (2014) (112)
The MDM2 promoter SNP285C/309G haplotype diminishes Sp1 transcription factor binding and reduces risk for breast and ovarian cancer in Caucasians. (2011) (111)
Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31 (2013) (110)
Tumor necrosis is an important hallmark of aggressive endometrial cancer and associates with hypoxia, angiogenesis and inflammation responses (2015) (106)
Biologic markers in endometrial cancer treatment (2009) (102)
Prognostic importance of various clinicopathological features in papillary thyroid carcinoma. (1992) (99)
Prognostic importance of glomeruloid microvascular proliferation indicates an aggressive angiogenic phenotype in human cancers. (2002) (98)
Association of vitamin D levels and risk of ovarian cancer: a Mendelian randomization study. (2016) (96)
Molecular profiling of circulating tumor cells links plasticity to the metastatic process in endometrial cancer (2013) (92)
Identification of high-risk patients by assessment of nuclear Ki-67 expression in a prospective study of endometrial carcinomas. (1998) (89)
Loss of PTEN expression is associated with metastatic disease in patients with endometrial carcinoma (2002) (88)
Recurrence of endometrial carcinoma and the value of routine follow up (1997) (88)
Significance of PTEN alterations in endometrial carcinoma: a population-based study of mutations, promoter methylation and PTEN protein expression. (2004) (87)
What Is the Best Preoperative Imaging for Endometrial Cancer? (2016) (86)
Staging of endometrial carcinomas with MRI using traditional and novel MRI techniques. (2012) (86)
High Diagnostic Value of 18F-FDG PET/CT in Endometrial Cancer: Systematic Review and Meta-Analysis of the Literature (2016) (86)
L1CAM expression in endometrial carcinomas: an ENITEC collaboration study (2016) (85)
Angiogenesis is prognostically important in vertical growth phase melanomas. (1999) (84)
Prognostic impact of histological grade and vascular invasion compared with tumour cell proliferation in endometrial carcinoma of endometrioid type (2004) (83)
Molecular pathogenesis and prognostic factors in endometrial carcinoma (2002) (82)
Genome-wide significant risk associations for mucinous ovarian carcinoma (2015) (81)
A Multifactorial Analysis of Factors Related to Lethality After Treatment of Perforated Gastroduodenal Ulcer (1989) (78)
GATA3 expression in estrogen receptor alpha-negative endometrial carcinomas identifies aggressive tumors with high proliferation and poor patient survival. (2008) (77)
Pathologic expression of p53 or p16 in preoperative curettage specimens identifies high-risk endometrial carcinomas. (2006) (77)
BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. (2016) (76)
KRAS gene amplification and overexpression but not mutation associates with aggressive and metastatic endometrial cancer (2012) (75)
High-throughput interrogation of PIK3CA, PTEN, KRAS, FBXW7 and TP53 mutations in primary endometrial carcinoma. (2013) (75)
Integrated Genomic Analysis of the 8q24 Amplification in Endometrial Cancers Identifies ATAD2 as Essential to MYC-Dependent Cancers (2013) (74)
Metabolic Tumor Volume on 18F-FDG PET/CT Improves Preoperative Identification of High-Risk Endometrial Carcinoma Patients (2015) (73)
A New Method for Isolation of Interstitial Fluid from Human Solid Tumors Applied to Proteomic Analysis of Ovarian Carcinoma Tissue (2011) (71)
Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer (2017) (70)
Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer (2014) (68)
Shared genetics underlying epidemiological association between endometriosis and ovarian cancer. (2015) (68)
Loss of progesterone receptor links to high proliferation and increases from primary to metastatic endometrial cancer lesions. (2014) (67)
Revision of FIGO surgical staging in 2009 for endometrial cancer validates to improve risk stratification. (2012) (67)
Onconeural antibodies in sera from patients with various types of tumours (2009) (66)
Five endometrial cancer risk loci identified through genome-wide association analysis (2016) (64)
Preoperative anemia, leukocytosis and thrombocytosis identify aggressive endometrial carcinomas. (2013) (64)
Elevated Plasma Growth Differentiation Factor-15 Correlates with Lymph Node Metastases and Poor Survival in Endometrial Cancer (2011) (64)
Significance of CD 105 expression for tumour angiogenesis and prognosis in endometrial carcinomas (2003) (61)
Adult body mass index and risk of ovarian cancer by subtype: a Mendelian randomization study. (2016) (60)
Independent prognostic importance of microvessel density in endometrial carcinoma. (1998) (60)
Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast–ovarian cancer susceptibility locus (2016) (58)
Papillary thyroid carcinoma: a multivariate analysis of prognostic factors including an evaluation of the p-TNM staging system. (1992) (58)
Prognostic impact of EGF-receptor in papillary thyroid carcinoma. (1993) (57)
ARID1A loss is prevalent in endometrial hyperplasia with atypia and low-grade endometrioid carcinomas (2013) (56)
Loss of GPER identifies new targets for therapy among a subgroup of ERα-positive endometrial cancer patients with poor outcome (2012) (55)
Somatic mutation profiles of clear cell endometrial tumors revealed by whole exome and targeted gene sequencing (2017) (54)
Genetic Risk Score Mendelian Randomization Shows that Obesity Measured as Body Mass Index, but not Waist:Hip Ratio, Is Causal for Endometrial Cancer (2016) (54)
MSI‐low, a real phenomenon which varies in frequency among cancer types (2003) (54)
Mutations in the DDR 2 Kinase Gene identify a Novel therapeutic target in squamous cell lung cancer (2011) (53)
Loss of hMSH2 and hMSH6 expression is frequent in sporadic endometrial carcinomas with microsatellite instability: a population-based study. (2002) (51)
SNP285C modulates oestrogen receptor/Sp1 binding to the MDM2 promoter and reduces the risk of endometrial but not prostatic cancer. (2012) (50)
Current Status of Molecular Biomarkers in Endometrial Cancer (2014) (50)
Preoperative Tumor Size at MRI Predicts Deep Myometrial Invasion, Lymph Node Metastases, and Patient Outcome in Endometrial Carcinomas (2014) (50)
Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer (2015) (50)
CYP19A1 fine-mapping and Mendelian randomization: estradiol is causal for endometrial cancer (2015) (50)
Molecular profiling of endometrial carcinoma precursor, primary and metastatic lesions suggests different targets for treatment in obese compared to non-obese patients (2014) (50)
Gene expression patterns related to vascular invasion and aggressive features in endometrial cancer. (2011) (49)
Importance of tumour cell invasion in blood and lymphatic vasculature among patients with endometrial carcinoma (2009) (48)
Low frequency of BRAF and CDKN2A mutations in endometrial cancer (2005) (48)
Standard 1.5-T MRI of endometrial carcinomas: modest agreement between radiologists (2012) (48)
Poorer survival of nulliparous women with endometrial carcinoma (1998) (48)
Lipocalin 2 expression is associated with aggressive features of endometrial cancer (2012) (48)
High BMI is significantly associated with positive progesterone receptor status and clinico-pathological markers for non-aggressive disease in endometrial cancer (2011) (47)
Androgen receptor as potential therapeutic target in metastatic endometrial cancer (2016) (47)
Fine-mapping of the HNF1B multicancer locus identifies candidate variants that mediate endometrial cancer risk (2014) (47)
Increased microvascular proliferation is negatively correlated to tumour blood flow and is associated with unfavourable outcome in endometrial carcinomas (2013) (46)
Low BMI-1 expression is associated with an activated BMI-1-driven signature, vascular invasion, and hormone receptor loss in endometrial carcinoma (2008) (46)
PTEN loss is a context‐dependent outcome determinant in obese and non‐obese endometrioid endometrial cancer patients (2015) (46)
High level of HSF1 associates with aggressive endometrial carcinoma and suggests potential for HSP90 inhibitors (2014) (43)
Added Value of Estrogen Receptor, Progesterone Receptor, and L1 Cell Adhesion Molecule Expression to Histology-Based Endometrial Carcinoma Recurrence Prediction Models: An ENITEC Collaboration Study (2018) (42)
Risk of ovarian cancer and the NF-κB pathway: genetic association with IL1A and TNFSF10. (2014) (42)
Yo antibodies in ovarian and breast cancer patients detected by a sensitive immunoprecipitation technique (2006) (41)
Tumour apparent diffusion coefficient is associated with depth of myometrial invasion and is negatively correlated to tumour volume in endometrial carcinomas. (2015) (41)
Loss of p63 and cytokeratin 5/6 expression is associated with more aggressive tumors in endometrial carcinoma patients (2006) (40)
Annexin‐A2 as predictor biomarker of recurrent disease in endometrial cancer (2015) (39)
HER-2/neu expression is associated with high tumor cell proliferation and aggressive phenotype in a population based patient series of endometrial carcinomas. (2008) (39)
Genome-Wide Association Study Identifies a Possible Susceptibility Locus for Endometrial Cancer (2012) (39)
ATAD2 overexpression links to enrichment of B-MYB-translational signatures and development of aggressive endometrial carcinoma (2015) (38)
Stathmin Protein Level, a Potential Predictive Marker for Taxane Treatment Response in Endometrial Cancer (2014) (37)
Fertility and gonadal function after adjuvant therapy in women diagnosed with a malignant ovarian germ cell tumor (MOGCT) during the "cisplatin era". (2015) (37)
Network-Based Integration of GWAS and Gene Expression Identifies a HOX-Centric Network Associated with Serous Ovarian Cancer Risk (2015) (36)
High Phospho-Stathmin(Serine38) Expression Identifies Aggressive Endometrial Cancer and Suggests an Association with PI3K Inhibition (2013) (35)
Somatic mutations are present in all members of the AKT family in endometrial carcinoma (2009) (35)
Clinicopathologic and molecular markers in cervical carcinoma: a prospective cohort study (2017) (35)
HER2 expression patterns in paired primary and metastatic endometrial cancer lesions (2017) (35)
High-Throughput Mutation Profiling of Primary and Metastatic Endometrial Cancers Identifies KRAS, FGFR2 and PIK3CA to Be Frequently Mutated (2012) (34)
Candidate locus analysis of the TERT–CLPTM1L cancer risk region on chromosome 5p15 identifies multiple independent variants associated with endometrial cancer risk (2014) (34)
Dynamic contrast-enhanced MRI in endometrial carcinoma identifies patients at increased risk of recurrence (2013) (33)
A discordant histological risk classification in preoperative and operative biopsy in endometrial cancer is reflected in metastatic risk and prognosis. (2013) (33)
Molecular differences between RER+ and RER– sporadic endometrial carcinomas in a large population‐based series (2004) (33)
Expression of L1CAM in curettage or high L1CAM level in preoperative blood samples predicts lymph node metastases and poor outcome in endometrial cancer patients (2017) (32)
Meta-analysis of genome-wide association studies identifies common susceptibility polymorphisms for colorectal and endometrial cancer near SH2B3 and TSHZ1 (2015) (32)
High visceral fat percentage is associated with poor outcome in endometrial cancer (2017) (31)
Deoxyribonucleic acid ploidy in endometrial carcinoma: a reproducible and valid prognostic marker in a routine diagnostic setting. (2009) (31)
Hypomethylation of the CTCFL/BORIS promoter and aberrant expression during endometrial cancer progression suggests a role as an Epi-driver gene (2014) (31)
Follow‐up routines in gynecological cancer – time for a change? (2011) (30)
Multimodal Imaging of Orthotopic Mouse Model of Endometrial Carcinoma (2015) (30)
Integrative Kinome Profiling Identifies mTORC1/2 Inhibition as Treatment Strategy in Ovarian Clear Cell Carcinoma (2018) (30)
Increased WD-repeat containing protein 1 in interstitial fluid from ovarian carcinomas shown by comparative proteomic analysis of malignant and healthy gynecological tissue. (2013) (29)
CDR2 antigen and Yo antibodies (2010) (29)
Tissue and imaging biomarkers for hypoxia predict poor outcome in endometrial cancer (2016) (28)
Potential Targets' Analysis Reveals Dual PI3K/mTOR Pathway Inhibition as a Promising Therapeutic Strategy for Uterine Leiomyosarcomas—an ENITEC Group Initiative (2017) (28)
The genetic landscape of 87 ovarian germ cell tumors. (2018) (28)
Improved survival related to changes in endometrial cancer treatment, a 30-year population based perspective. (2012) (27)
Evolution in Endometrial Cancer: Evidence From an Immunohistochemical Study (2011) (26)
Polymorphisms in Inflammation Pathway Genes and Endometrial Cancer Risk (2012) (26)
Parity and Time Interval Since Childbirth Influence Survival in Endometrial Cancer Patients (2008) (26)
Where to give birth? Politics and the place of birth. (2001) (26)
Common Genetic Variation in Circadian Rhythm Genes and Risk of Epithelial Ovarian Cancer (EOC) (2015) (26)
What (and why) do women want? The desires of women and the design of maternity care. (2001) (25)
High mRNA levels of 17β-hydroxysteroid dehydrogenase type 1 correlate with poor prognosis in endometrial cancer (2017) (25)
Switch in FOXA1 Status Associates with Endometrial Cancer Progression (2014) (25)
GALR1 Methylation in Vaginal Swabs Is Highly Accurate in Identifying Women With Endometrial Cancer (2013) (25)
Loss of estrogen receptor (ER) expression in endometrial tumors is not associated with de novo methylation of the 5' end of the ER gene. (2000) (25)
DNA ploidy in curettage specimens identifies high-risk patients and lymph node metastasis in endometrial cancer (2015) (25)
Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA (2013) (24)
White Blood Cell BRCA1 Promoter Methylation Status and Ovarian Cancer Risk (2018) (24)
A Common Variant at the 14q32 Endometrial Cancer Risk Locus Activates AKT1 through YY1 Binding. (2016) (24)
Magnetic resonance imaging performs better than endocervical curettage for preoperative prediction of cervical stromal invasion in endometrial carcinomas. (2012) (23)
Ri antibodies in patients with breast, ovarian or small cell lung cancer determined by a sensitive immunoprecipitation technique (2006) (23)
Comprehensive genetic assessment of the ESR1 locus identifies a risk region for endometrial cancer. (2015) (23)
Loss of ASRGL1 expression is an independent biomarker for disease-specific survival in endometrioid endometrial carcinoma. (2015) (23)
Growth Differentiation Factor-15 as Biomarker in Uterine Sarcomas (2014) (23)
Assessing the genetic architecture of epithelial ovarian cancer histological subtypes (2016) (22)
Prognostic impact of morphometric nuclear grade of endometrial carcinoma (1998) (22)
Integrative Protein-Based Prognostic Model for Early-Stage Endometrioid Endometrial Cancer (2015) (21)
Blocking 17β‐hydroxysteroid dehydrogenase type 1 in endometrial cancer: a potential novel endocrine therapeutic approach (2018) (21)
Epithelial‐Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) Risk (2015) (21)
Cerebellar degeneration-related proteins 2 and 2-like are present in ovarian cancer in patients with and without Yo antibodies (2017) (20)
The Role of Adjuvant Chemotherapy in Surgical Stages I-II Serous and Clear Cell Carcinomas and Carcinosarcoma of the Endometrium: A Collaborative Study (2010) (20)
The MDM4 SNP34091 (rs4245739) C-allele is associated with increased risk of ovarian—but not endometrial cancer (2016) (20)
Comparison of nucleic acid targets prepared from total RNA or poly(A) RNA for DNA oligonucleotide microarray hybridization. (2007) (19)
Enrichment of putative PAX8 target genes at serous epithelial ovarian cancer susceptibility loci (2017) (19)
A national, prospective observational study of first recurrence after primary treatment for gynecological cancer in Norway (2017) (18)
PI3K pathway in gynecologic malignancies. (2013) (18)
Molecular assessment of depth of myometrial invasion in stage I endometrial cancer: a model based on K-ras mutation analysis. (2003) (18)
No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. (2016) (18)
Stathmin is superior to AKT and phospho‐AKT staining for the detection of phosphoinositide 3‐kinase activation and aggressive endometrial cancer (2010) (18)
PIK3CA exon9 mutations associate with reduced survival, and are highly concordant between matching primary tumors and metastases in endometrial cancer (2017) (18)
Thyroid carcinoma: results from surgical treatment in 211 consecutive patients. (1991) (18)
Evaluating the ovarian cancer gonadotropin hypothesis: a candidate gene study. (2015) (17)
Gynecologic Cancer InterGroup (GCIG) Endometrial Cancer Clinical Trials Planning Meeting: Taking Endometrial Cancer Trials Into the Translational Era (2013) (17)
Methylation of hMLH 1 in a Population-based Series of Endometrial Carcinomas 1 (2000) (16)
Asparaginase-like protein 1 is an independent prognostic marker in primary endometrial cancer, and is frequently lost in metastatic lesions. (2018) (16)
Increased angiogenesis is associated with a 32-gene expression signature and 6p21 amplification in aggressive endometrial cancer (2015) (16)
Endometrial cancer cells exhibit high expression of p110β and its selective inhibition induces variable responses on PI3K signaling, cell survival and proliferation (2016) (15)
Diagnostic screening of NEUROD1 (MODY6) in subjects with MODY or gestational diabetes mellitus (2005) (15)
MDM2 promoter polymorphism del1518 (rs3730485) and its impact on endometrial and ovarian cancer risk (2017) (15)
Influence of p53 Isoform Expression on Survival in High-Grade Serous Ovarian Cancers (2019) (15)
MDM2 Promoter SNP344T>A (rs1196333) Status Does Not Affect Cancer Risk (2012) (15)
Follow‐up of gynecological cancer patients after treatment – the views of European experts in gynecologic oncology (2012) (14)
Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17 q 21 . 31 (2013) (14)
Prognostic Impact of Parity in 493 Uterine Sarcoma Patients (2009) (14)
Recurrent hormone-binding domain truncated ESR1 amplifications in primary endometrial cancers suggest their implication in hormone independent growth (2016) (14)
PIK3CA Amplification Associates with Aggressive Phenotype but Not Markers of AKT-MTOR Signaling in Endometrial Carcinoma (2018) (14)
C77G in PTPRC (CD45) is no risk allele for ovarian cancer, but associated with less aggressive disease (2017) (13)
Intra-Gene DNA Methylation Variability Is a Clinically Independent Prognostic Marker in Women’s Cancers (2015) (13)
Plasma calprotectin concentrations in women with endometrial carcinoma. (2009) (13)
in squamous cell lung cancer (2011) (13)
Distribution volumes of macromolecules in human ovarian and endometrial cancers--effects of extracellular matrix structure. (2015) (12)
Expression of glucocorticoid receptor is associated with aggressive primary endometrial cancer and increases from primary to metastatic lesions. (2017) (12)
Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study (2018) (12)
Clinical value of DNA content assessment in endometrial cancer (2014) (12)
Fine-mapping of the HNF 1 B multicancer locus identi fi es candidate variants thatmediate endometrial cancer risk (2015) (11)
Consortium analysis of gene and gene-folate interactions in purine and pyrimidine metabolism pathways with ovarian carcinoma risk. (2014) (11)
ESGO Statement on the Role of CA‐125 Measurement in Follow-Up of Epithelial Ovarian Cancer (2012) (10)
Quantification of the concentration gradient of biomarkers between ovarian carcinoma interstitial fluid and blood (2014) (9)
Late-week surgical treatment of endometrial cancer is associated with worse long-term outcome: Results from a prospective, multicenter study (2017) (9)
Changes in Chromatin Structure in Curettage Specimens Identifies High-Risk Patients in Endometrial Cancer (2016) (9)
Endometrial Carcinoma Recurrence Score (ECARS) validates to identify aggressive disease and associates with markers of epithelial-mesenchymal transition and PI3K alterations. (2014) (9)
Identification of highly connected and differentially expressed gene subnetworks in metastasizing endometrial cancer (2018) (9)
Clinical value of dna content assessment in endometrial cancer. (2014) (9)
Training in Bowel and Upper Abdominal Surgery in Gynaecological Oncology: European Society of Gynecological Oncology (ESGO) Statement (2011) (9)
Stratification based on high tumour cell content in fresh frozen tissue promotes selection of aggressive endometrial carcinomas (2012) (8)
Molecular determinants of outcome with mTOR inhibition in endometrial cancer (EC). (2012) (8)
Preoperative imaging markers and PDZ-binding kinase tissue expression predict low-risk disease in endometrial hyperplasias and low grade cancers (2017) (7)
Expression of L 1 CAM in curettage or high L 1 CAM level in preoperative blood samples predicts lymph node metastases and poor outcome in endometrial cancer patients (2017) (5)
[Routine follow up after treatment for gynecological cancer]. (2001) (4)
Type of vascular invasion in association with progress of endometrial cancer (2017) (4)
Meta-analysis of genome-wide association studies identifies common susceptibility polymorphisms for colorectal and endometrial cancer near SH 2 B 3 and TSHZ 1 (2015) (4)
Aneuploidy related transcriptional changes in endometrial cancer link low expression of chromosome 15q genes to poor survival (2016) (4)
Candidate locus analysis of the TERT–CLPTM1L cancer risk region on chromosome 5p15 identifies multiple independent variants associated with endometrial cancer risk (2014) (4)
Loss of hMSH 2 and hMSH 6 Expression Is Frequent in Sporadic Endometrial Carcinomas with Microsatellite Instability : A Population-based Study 1 (2002) (3)
Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer (2016) (3)
Analyses of germline variants associated with ovarian cancer survival identify functional candidates at the 1q22 and 19p12 outcome loci. (2017) (3)
Subspecialist training in surgical gynecologic oncology in the Nordic countries (2011) (3)
Correction: The Dynamics and Prognostic Potential of DNA Methylation Changes at Stem Cell Gene Loci in Women's Cancer (2012) (3)
Lipocalin 2 expression is associated with aggressive features of endometrial cancer (2012) (2)
Polymorphisms in In fl ammation Pathway Genes and Endometrial Cancer Risk (2013) (2)
Impact of the MDM2 promoter polymorphisms SNP285 and SNP309 on endometrial cancer risk among caucasians. (2011) (2)
Novel PCDH10-Wnt-MALAT1 regulatory axis in endometrioid endometrial adenocarcinoma. (2019) (2)
Integrated analysis of cervical squamous cell carcinoma cohorts from three continents reveals conserved subtypes of prognostic significance (2021) (2)
Common variants at the CHEK 2 gene locus and risk of epithelial ovarian cancer (2015) (2)
Analyses of germline variants associated with ovarian cancer survival identify functional candidates at the 1q22 and 19p12 outcome loci (2017) (2)
Molekylærdiagnostiske metoder innen gynekologisk kreft (2005) (1)
[Mass screening against endometrial carcinoma]. (2002) (1)
Common variants at the CHEK2 gene locus and risk of epithelial ovarian cancer. (2015) (1)
Molecular profiling of circulating tumor cells links plasticity to the metastatic process in endometrial cancer (2014) (1)
F-fluorodeoxyglucose Positron Emission Tomography / Computed Tomography ( 18 F-FDG-PET / CT ) improves preoperative identification of high-risk endometrial carcinoma patients (2015) (1)
Distinct copy number alteration patterns as prognostic of endometrial cancer outcomes. (2013) (1)
High Phospho-Stathmin ( Serine 38 ) Expression Identi fi es AggressiveEndometrialCancerandSuggestsanAssociation with PI 3 K Inhibition (2013) (1)
[Molecular diagnostic techniques in gynaecologic cancer]. (2005) (1)
Fine-mapping of the HNF1Bmulticancer locus identifies candidate variants thatmediate endometrial cancer risk (2015) (1)
Abstract 331: C-MYC gene amplification in endometrial cancer is associated with aggressive tumors (2011) (1)
Abstracts from 18th International Meeting of the European Society of Gynaecological Oncology (ESGO), 19-22 October 2013, Liverpool, UK (2013) (1)
Molecular profiling in fresh tissue with high tumor cell content promotes enrichment for aggressive adenocarcinomas in cervix. (2014) (1)
Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study (2018) (1)
Abstract 3158: Stathmin expression predicts response to taxanes in metastatic endometrial cancer (2011) (1)
[Staffing and emergency service in Norwegian obstetrics and gynecology departments]. (2004) (1)
Abstract 4604: Landscape of human and viral genomic alterations in cervical carcinomas. (2013) (1)
Mendelian randomization Association of vitamin D levels and risk of ovarian cancer : a Mendelian randomization study (2016) (0)
CDR2 antigen and Yo antibodies Cecilie TotlandNina K. AarskogTilo W. EichlerMette Haugen • Jane K. NøstbakkenSissel E. MonstadHelga B. SalvesenSverre Mørk • Bjørn I. HaukanesChristian A. Vedeler (2011) (0)
Abstract 3864: Aneuploidy predicts aggressiveness and poor prognosis in endometrial cancer, and is reflected in a 9-gene signature (2015) (0)
Abstract 2875: ATAD2 overexpression indentifies aggressive endometrial carcinomas (2014) (0)
HER-2/neu expression is associated with increased tumor cell proliferation, loss of hormone receptors and an aggressive phenotype in a population based setting of endometrial carcinomas (2007) (0)
MDM2 promoter polymorphism del1518 (rs3730485) and its impact on endometrial and ovarian cancer risk (2017) (0)
A discordant histological risk classification in preoperative biopsy and hysterectomy specimens in endometrial cancer is reflected in metastatic risk and prognosis (2012) (0)
Supplementary Information for HOTAIR AND ITS SURROGATE DNA METHYLATION SIGNATURE INDICATE CARBOPLATIN RESISTANCE IN OVARIAN CANCER (2015) (0)
Texture analysis of 2D spatial distribution of blood pharmacokinetic model parameters for endometrial carcinoma classification (2016) (0)
Assessing the genetic architecture of epithelial ovarian cancer histological subtypes (2016) (0)
HIGH LEVEL OF NUCLEAR HEAT-SHOCK FACTOR 1 (HSF1) ASSOCIATES WITH AGGRESSIVE DISEASE AND SUGGESTS TARGETS FOR THERAPY IN ENDOMETRIAL CARCINOMA (2013) (0)
Corrigendum: Recurrent hormone-binding domain truncated ESR1 amplifications in primary endometrial cancers suggest their implication in hormone independent growth (2017) (0)
Abstract 4731: High level of nuclear heat-shock factor 1 is associated with aggressive disease and suggests targets for therapy in endometrial carcinoma (2014) (0)
[If the woman giving birth had her choice... Results of a consumer study in the region of Bergen]. (1995) (0)
Abstract 4692: Relationships between somatic genomic alterations, tumor stage and progression-free survival in cervical cancer (2014) (0)
Common variants at theCHEK2gene locus and risk of epithelial ovarian cancer (2015) (0)
DCE-MRI in Endometrial Carcinomas (2011) (0)
Abstract 4613: MDM4 SNP 34091 (rs4245739) effect on risk of breast, colon, lung, prostate, endometrial and ovarian cancer (2015) (0)
KRAS, PIK3CA, TP53 and FBWX7 Mutations as Prognostic Markers For Primary Endometrial Cancer (2011) (0)
222 INVITED New Targets for Personalised Medicine in Endometrial Cancer (2011) (0)
The PTEN gene is methylated in endometrial carcinoma and associated with advanced disease and microsatellite instability. (1999) (0)
Macromolecular Distribution Volume in Human Ovarian and Endometrial Cancer (2015) (0)
PIK3CA exon9 mutations associate with reduced survival, and are highly concordant between matching primary tumors and metastases in endometrial cancer (2017) (0)
Influence of p53 Isoform Expression on Survival in High-Grade Serous Ovarian Cancers (2019) (0)
Abstract LB-120: HER2 as a potential predictive marker and target for therapy in cervical cancer (2015) (0)
Increased 17beta-hydroxysteroid dehydrogenase type 1 mRNA level is correlated with poor prognosis in endometrial cancer (2016) (0)
[Late, but good]. (2008) (0)
Sent, men godt (2008) (0)
Unveiling mutations behind cervical cancer (2018) (0)
Corrigendum: Recurrent hormone-binding domain truncated ESR1 amplifications in primary endometrial cancers suggest their implication in hormone independent growth (2016) (0)
PATHOLOGIC P53 EXPRESSION IN PREOPERATIVE CURETTAGE SPECIMENS IDENTIFIES THE HIGH-RISK ENDOMETRIAL CARCINOMAS (2004) (0)
Pro-metastatic gene expression, immune evasion and an altered HPV spectrum characterize an aggressive subtype of cervical cancer (2020) (0)
Hormone receptor status in endometrial carcinoma curettage independently predicts lymph node metastasis and prognosis in a multicentre setting (2010) (0)
HOTAIR and its surrogate DNA methylation signature indicate carboplatin resistance in ovarian cancer (2015) (0)
[Role of lymphadenectomy in the surgery of gynecologic cancer]. (2001) (0)
Molecular differences between RER+ and RER– sporadic endometrial carcinomas in a large population-based series (2004) (0)
Abstract 4502: DNA ploidy in tumor correlates with age, and explains some of the poor prognostic impact of age in endometrial carcinomas (2012) (0)
Patterns of gene expression related to vascular invasion and aggressive features in endometrial cancer (2007) (0)
Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA (2013) (0)
Abstract 330: Gene expression signature characterized by PI3Kinase activation and Stathmin overexpression validates to identify aggressive disease and a potential for PI3Kinase-inhibitors in endometrial carcinomas (2011) (0)
Abstract LB-331: Polymorphisms in inflammation pathway genes and endometrial cancer (2012) (0)
Quanti fi cation of the concentration gradient of biomarkers between ovarian carcinoma interstitial fl uid and blood (2014) (0)
Abstract 4169: Loss of GPR30 expression identifies estrogen receptor positive endometrial carcinoma patients with poor outcome (2011) (0)
randomization Association of vitamin D levels and risk of ovarian cancer: a Mendelian randomization study (2016) (0)

This paper list is powered by the following services:

Other Resources About Helga Salvesen

en.wikipedia.org

What Schools Are Affiliated With Helga Salvesen?

Helga Salvesen is affiliated with the following schools:

University of Bergen